ROIV (Roivant Sciences) Tax Rate %: 21.66% (As of Mar. 2026)


ROIV Roivant Sciences Ltd ROIV
55 GF Score
Price $35.14
GF Value $11.03
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Tax Rate %?

Roivant Sciences ROIV +0.29% 55 Tax Rate % is 21.66% as of Mar. 2026. GuruFocus rates ROIV with a GF Score™ of 55/100 and a GF Value™ of $11.03 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Roivant Sciences's Tax Expense for the three months ended in Mar. 2026 was $98.35 Mil. Roivant Sciences's Pre-Tax Income for the three months ended in Mar. 2026 was $454.10 Mil. Therefore, Roivant Sciences's Tax Rate % for the quarter that ended in Mar. 2026 was 21.66%.

Roivant Sciences Tax Rate % Related Terms

Roivant Sciences Tax Rate % Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences Tax Rate % Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Tax Rate %
Get a 7-Day Free Trial -0.04 -0.46 0.47 -7.07 -50.39

Roivant Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.29 -1.73 -4.40 -8.04 21.66
ROIV
55GF Score
Roivant Sciences Ltd ROIV
Tax Rate % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Roivant Sciences's Tax Rate % for the fiscal year that ended in Mar. 2026 is calculated as

Tax Rate %=Tax Expense (A: Mar. 2026 )/Pre-Tax Income (A: Mar. 2026 )
=133.329/-264.578
=-50.39 %

Roivant Sciences's Tax Rate % for the quarter that ended in Mar. 2026 is calculated as

Tax Rate %=Tax Expense (Q: Mar. 2026 )/Pre-Tax Income (Q: Mar. 2026 )
=98.353/454.097
=21.66 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Rate % →
What does a Tax Rate % of 21.66% mean?
Roivant Sciences (ROIV) has a Tax Rate % of 21.66% as of Mar. 2026.
Is Roivant Sciences' Tax Rate % too high?
Roivant Sciences' current Tax Rate % is 21.66%. Overall, Roivant Sciences has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Tax Rate % compare to RPRX and BNTX?
Roivant Sciences' Tax Rate % of 21.66% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Rate % for a Biotechnology company?
A good Tax Rate % depends on the Biotechnology industry context. However, Tax Rate % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Rate % mean?
A high Tax Rate % can signal that a stock is expensive relative to its fundamentals. Roivant Sciences's current Tax Rate % is 21.66%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $11.03, compared to a current price of $35.14 — trading 218.6% above its estimated fair value. The current Tax Rate % is 21.66%. Roivant Sciences' overall GF Score™ is 55/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Rate % calculated?
Tax Rate % is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Tax Rate % is 21.66% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roivant Sciences (ROIV) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of $35.14 is trading 218.6% above its estimated GF Value™ of $11.03. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for ROIV:

  • Tax Rate %: 21.66%
  • GF Value™: $11.03 vs. price of $35.14 (218.6% above fair value)
  • GF Score™: 55/100 with 7 warning signs

No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roivant Sciences Business Description

Other Exchanges 87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
55GF Score

Get the complete analysis for ROIV

Tax Rate % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.14
Price
$11.03
GF Value